Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus.
Arginine-vasopressin (AVP) is synthesized and released centrally in several brain structures. AVP is thought to mediate anxiety-related behavior through two central receptor subtypes, Avpr1a and Avpr1b. Although these AVP receptor subtypes are expressed in several brain regions, including the hippocampus, little is known about their explicit role in unconditioned fear or anxiety. This experiment assessed the anxiety-related effects of a selective Avpr1a antagonist ([beta-Mercapto-beta,beta-cyclopentamethylenepropionyl1, O-me-Tyr2, Arg8]-AVP) and a selective Avpr1b antagonist ((2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide; SSR 149415) microinfused into either the dorsal or ventral sub-regions of the rat hippocampus. Avpr1a antagonism in the ventral, but not the dorsal hippocampus reduced rats' anxiety-like behavior in the elevated plus-maze test. Conversely, Avpr1b antagonism in the dorsal, but not the ventral, hippocampus reduced anxiety in the plus-maze test. Neither antagonist reduced anxiety-like behavior in the shock-probe burying test. Overall, the results show that both receptor subtypes of AVP are involved in anxiety-related responses, but their specific contributions depend on three variables: (1) the anxiety-related response (shock-probe avoidance versus open-arm avoidance), (2) the receptor subtype antagonized (Avpr1a versus Avpr1b), and (3) the area of hippocampus (dorsal versus ventral) into which these antagonists are infused. These dissociations suggest that different fear responses are under the control of specific AVP receptor systems within discrete parts of the hippocampus.
Department of Psychology and Division of Neuroscience, P-449 Biological Sciences Building, University of Alberta, Edmonton, AB, Canada T6G 2E9.
Elif
E
Engin
Dallas
D
Treit
D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D065092:Antidiuretic Hormone Receptor Antagonists; D001007:Anxiety / Q000188:drug therapy; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D005239:Fear / Q000187:drug effects / Q000502:physiology; D006624:Hippocampus / Q000033:anatomy & histology / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017483:Receptors, Vasopressin / Q000378:metabolism
D014151:Anti-Anxiety Agents; D065092:Antidiuretic Hormone Receptor Antagonists; D017483:Receptors, Vasopressin